<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; agreement</title>
	<atom:link href="http://www.tapanray.in/tag/agreement/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Deadly Climate Change Impact On Human Health: How Prepared Is India?</title>
		<link>http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=deadly-climate-change-impact-on-human-health-how-prepared-is-india</link>
		<comments>http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/#comments</comments>
		<pubDate>Mon, 12 Aug 2019 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[Ayushman]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change. global]]></category>
		<category><![CDATA[Climate]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Ebola]]></category>
		<category><![CDATA[effect]]></category>
		<category><![CDATA[gainers]]></category>
		<category><![CDATA[greenhouse]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infectious diseases]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Paris]]></category>
		<category><![CDATA[problems]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[researching]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tropical]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[warming]]></category>
		<category><![CDATA[Zika]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9665</guid>
		<description><![CDATA[It’s not uncommon to find many people, including heads of countries, expressing their serious apprehensions in public, about the scary impact of climate change. Just the last year, on November 26, 2018, BBC News captured one of such incidences with the astonishing &#8230; <a href="http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TPP: Discord Within A Strange Mélange And Impact On Access To Medicines</title>
		<link>http://www.tapanray.in/tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines</link>
		<comments>http://www.tapanray.in/tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines/#comments</comments>
		<pubDate>Mon, 25 May 2015 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[access to medicines]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[Asia-Pacific]]></category>
		<category><![CDATA[democrats]]></category>
		<category><![CDATA[discord]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[geopolitical]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mélange]]></category>
		<category><![CDATA[Pacific]]></category>
		<category><![CDATA[Partnership]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TPP]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[Trans]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WikiLeaks]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6665</guid>
		<description><![CDATA[On May 19, 2015, Bloomberg reported that a sizable number of President Barack Obama’s own party colleagues, besides teachers, seniors, Internet freedom groups and nuns, have joined the push to defeat the proposed Trans-Pacific Partnership (TPP) treaty. Before I delve into the TPP, &#8230; <a href="http://www.tapanray.in/tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>R&amp;D: Is Indian Pharma Moving Up the Value Chain?</title>
		<link>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rd-is-indian-pharma-moving-up-the-value-chain</link>
		<comments>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/#comments</comments>
		<pubDate>Mon, 02 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[analogue]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[Cadilla]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[diabetic]]></category>
		<category><![CDATA[Dr]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[dyslipidemia]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[falciparum]]></category>
		<category><![CDATA[Forest]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glitazar]]></category>
		<category><![CDATA[hibernation]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Jubilant]]></category>
		<category><![CDATA[lab]]></category>
		<category><![CDATA[Leap]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Lipaglyn]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[mass]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[plasmodium]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy's]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Rotavac]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Synrium]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Torrent]]></category>
		<category><![CDATA[universities]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3530</guid>
		<description><![CDATA[It almost went unnoticed by many, when in the post product patent regime, Ranbaxy launched its first homegrown ‘New Drug’ of India, Synriam, on April 25, 2012, coinciding with the ‘World Malaria Day’. The drug is used in the treatment &#8230; <a href="http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Ghost Keeps Haunting: NCD Dogs Cancer in &#8216;Compulsory License&#8217; Debate of India</title>
		<link>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india</link>
		<comments>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/#comments</comments>
		<pubDate>Mon, 11 Mar 2013 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Citizens']]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[collective]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Dasatinib]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[dogs]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[ghost]]></category>
		<category><![CDATA[haunting]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Ixabepilone]]></category>
		<category><![CDATA[keeps]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[leukemia]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[protein]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[treat]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[used]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2037</guid>
		<description><![CDATA[In November 2012, as a part of the ‘Campaign for Affordable Trastuzumab’ for the treatment of breast cancer, a citizens’ collective, reportedly sent an ‘Open Letter’ signed by around 200 cancer survivors, women’s groups, human rights and health rights campaigns &#8230; <a href="http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>EU-FTA, TRIPS-Plus provisions, Data Exclusivity, Public Interest and India</title>
		<link>http://www.tapanray.in/eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india</link>
		<comments>http://www.tapanray.in/eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india/#comments</comments>
		<pubDate>Sun, 30 Jan 2011 11:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[&]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[EUFTA]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Interest. and]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[plus]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Provisions]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=308</guid>
		<description><![CDATA[Business Standard in its January 27, 2011 edition reported, “Data Exclusivity still key hurdle to India-EU FTA” Before deliberating on this important issue of “Free Trade Agreement (FTA)”, let me touch upon very briefly, for the benefit of all concerned, &#8230; <a href="http://www.tapanray.in/eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
